Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
33
GRX Quote, Financials, Valuation and Earnings
Last price:
$9.62
Seasonality move
:
1.61%
Day range:
$9.48 - $9.82
52-week range:
$9.16 - $11.24
Dividend yield:
0.2%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
61.4K
Avg. volume:
26.3K
1-year change:
6.87%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingGabelli Healthcare & WellnessRx Trust has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Gabelli Healthcare & WellnessRx Trust has an estimated downside of -- from its current price of $9.65.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $9.65.
Fair Value
-
According to the consensus of 0 analysts, Gabelli Healthcare & WellnessRx Trust has -- downside to fair value with a price target of -- per share.
GRX vs. S&P 500
-
Over the past 5 trading days, Gabelli Healthcare & WellnessRx Trust has underperformed the S&P 500 by -2.13% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Gabelli Healthcare & WellnessRx Trust does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Gabelli Healthcare & WellnessRx Trust has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Gabelli Healthcare & WellnessRx Trust reported revenues of --.
Earnings Growth
-
Gabelli Healthcare & WellnessRx Trust has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Gabelli Healthcare & WellnessRx Trust reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-23 | 2023-12-23 | 2023-12-23 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $405.5K | $380.9K | $5.1M | |
| Total Assets | -- | -- | $272.3M | $307M | $286.5M | |
| Current Liabilities | -- | -- | $560.3K | $1.1M | $4M | |
| Total Liabilities | -- | -- | $688.3K | $1.3M | $44.3M | |
| Total Equity | -- | -- | $271.6M | $305.8M | $242.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-23 | 2023-12-23 | 2023-12-23 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
GRX
Sector
Market Cap
--
--
Price % of 52-Week High
85.85%
--
Dividend Yield
0.2%
--
Shareholder Yield
--
--
1-Year Price Total Return
6.87%
--
Beta (5-Year)
1.060
--
Dividend yield:
0.2%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$9.92
200-day SMA
Sell
Level
$10.17
Bollinger Bands (100)
Sell
Level
10.23 - 10.99
Chaikin Money Flow
Buy
Level
2M
20-day SMA
Sell
Level
$10.19
Relative Strength Index (RSI14)
Sell
Level
26.83
ADX Line
Buy
Level
9.18
Williams %R
Buy
Level
-85.2174
50-day SMA
Sell
Level
$10.37
MACD (12, 26)
Sell
Level
-0.19
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
6.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
Stock Forecast FAQ
In the current month, GRX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GRX average analyst price target in the past 3 months is --.
-
Where Will Gabelli Healthcare & WellnessRx Trust Stock Be In 1 Year?
According to analysts, the consensus estimate is that Gabelli Healthcare & WellnessRx Trust share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Gabelli Healthcare & WellnessRx Trust?
Analysts are divided on their view about Gabelli Healthcare & WellnessRx Trust share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Gabelli Healthcare & WellnessRx Trust is a Sell and believe this share price will rise from its current level to --.
-
What Is Gabelli Healthcare & WellnessRx Trust's Price Target?
The price target for Gabelli Healthcare & WellnessRx Trust over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Gabelli Healthcare & WellnessRx Trust is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GRX?
You can purchase shares of Gabelli Healthcare & WellnessRx Trust via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Gabelli Healthcare & WellnessRx Trust shares.
-
What Is The Gabelli Healthcare & WellnessRx Trust Share Price Today?
Gabelli Healthcare & WellnessRx Trust was last trading at $9.62 per share. This represents the most recent stock quote for Gabelli Healthcare & WellnessRx Trust. Yesterday, Gabelli Healthcare & WellnessRx Trust closed at $9.65 per share.
-
How To Buy Gabelli Healthcare & WellnessRx Trust Stock Online?
In order to purchase Gabelli Healthcare & WellnessRx Trust stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
